Source:http://linkedlifedata.com/resource/pubmed/id/10063485
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1999-5-3
|
pubmed:abstractText |
The benzodiazepines flunitrazepam, diazepam, and Ro 15-1788 and the beta-carboline DMCM bind with equivalent affinity to the benzodiazepine binding site of GABAA receptors containing different alpha subunits (i.e., alpha 1, alpha 2, alpha 3, or alpha 5); whereas, the triazolopyridazine CL 218,872 and imidazopyridine zolpidem have higher affinity for alpha 1 subunit-containing GABAA receptors. In the present study, the in vivo binding of [3H]Ro 15-1788 in mouse cerebellum and spinal cord was used to establish the occupancy of the benzodiazepine binding site of GABAA receptors containing primarily alpha 1 and alpha 2/alpha 3 subunits, respectively. Thus, the nonselective compounds flunitrazepam, diazepam, and DMCM all produced a similar inhibition of binding in cerebellum and spinal cord (respective ID50 values of 0.2 to 0.3 mg/kg, 2 mg/kg, and 10 mg/kg i.p.); whereas, the alpha 1 selective compounds CL 218,872 and zolpidem were more potent at inhibiting [3H]Ro 15-1788 binding in the cerebellum (ID50 values 4.5 mg/kg and 10 mg/kg i.p.) compared to the spinal cord (ID50 values 12 mg/kg and > 30 mg/kg i.p.). Thus, the reduction of in vivo f[3H]Ro 15-1788 binding in tissues containing alpha 1 and alpha 2/alpha 3 receptor populations reflects the in vitro affinities of subtype selective compounds and should help to interpret the behavioral profile of such compounds.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/CL 218872,
http://linkedlifedata.com/resource/pubmed/chemical/Flumazenil,
http://linkedlifedata.com/resource/pubmed/chemical/GABA Modulators,
http://linkedlifedata.com/resource/pubmed/chemical/GABA-A Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridazines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, GABA-A,
http://linkedlifedata.com/resource/pubmed/chemical/Tritium,
http://linkedlifedata.com/resource/pubmed/chemical/zolpidem
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0893-133X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
255-62
|
pubmed:dateRevised |
2011-5-18
|
pubmed:meshHeading |
pubmed-meshheading:10063485-Animals,
pubmed-meshheading:10063485-Benzodiazepines,
pubmed-meshheading:10063485-Binding Sites,
pubmed-meshheading:10063485-Cerebellum,
pubmed-meshheading:10063485-Flumazenil,
pubmed-meshheading:10063485-GABA Modulators,
pubmed-meshheading:10063485-GABA-A Receptor Antagonists,
pubmed-meshheading:10063485-Ligands,
pubmed-meshheading:10063485-Male,
pubmed-meshheading:10063485-Mice,
pubmed-meshheading:10063485-Pyridazines,
pubmed-meshheading:10063485-Pyridines,
pubmed-meshheading:10063485-Receptors, GABA-A,
pubmed-meshheading:10063485-Spinal Cord,
pubmed-meshheading:10063485-Time Factors,
pubmed-meshheading:10063485-Tritium
|
pubmed:year |
1999
|
pubmed:articleTitle |
Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for alpha 1 versus alpha 2 and alpha 3 subunit-containing GABAA receptors.
|
pubmed:affiliation |
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Essex, UK.
|
pubmed:publicationType |
Journal Article,
In Vitro
|